Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | NOS2 | P35228 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27502508 | 0.98 | NOS1 (0.47) | LOXL2NOS1NOS2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27521374 | 0.97 | NOS1 (0.46) | LOXL2NOS1NOS2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27521088 | 0.89 | ACHE (0.49) | NOS1ALDH1A1TYRACHENPC1 | |
| SCHEMBL5691933 | 0.86 | LOXL2 (0.47) | LOXL2NOS1NOS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6233836 | 0.85 | SMN1; SMN2 (0.45) | LOXL2ALDH1A1SMN1; SMN2CYP3A4CA12 | |
| SCHEMBL1992145 | 0.85 | CYP4F2 (0.53) | ALDH1A1TYRCA12CA1CA4 | |
| SCHEMBL27637243 | 0.85 | ALDH1A1 (0.46) | ALDH1A1TYRCA12CA1CA4 | |
| SCHEMBL1560391 | 0.85 | CYP4F2 (0.53) | ALDH1A1TYRCA12CA1CA4 | |
| SCHEMBL27551658 | 0.84 | LOXL2 (0.44) | LOXL2NOS1NOS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5776297 | 0.84 | CYP1A2 (0.41) | LOXL2ALDH1A1SMN1; SMN2CYP3A4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101610764-B | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LTD | 2012-11-21 | — | — | CN | disclosed |
| CN-102119141-A | Novel polymorphic forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid | GLAXO GROUP LTD | 2011-07-06 | — | — | CN | disclosed |
| CN-102119138-A | Novel salts of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid | GLAXO GROUP LTD | 2011-07-06 | — | — | CN | disclosed |
| CN-101610764-A | As EP 4The heterocyclic carbamate derivatives of receptor stimulating agent | GLAXO GROUP LTD (GB) | 2009-12-23 | — | — | CN | disclosed |
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| EP-1615890-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | LOXL2 3974/4885NOS1 2642/4885NOS2 2333/4885 |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | LOXL2 3183/4885NOS1 3596/4885NOS2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.